A single injection once a week, instead of a daily shot, can control blood sugar in people with type 2 diabetes just as effectively as the standard daily treatment.
That is the headline finding from the QWINT-1 trial, a major Phase 3 clinical study published in The New England Journal of Medicine and presented at the American Diabetes Association’s 85th Scientific Sessions in June 2025.
The drug at the centre of this development is efsitora alfa, a new once-weekly basal insulin developed by pharmaceutical company Eli Lilly.
It works differently from the daily insulins millions of people currently rely on, and it could, if approved by regulators, slash the number of injections a diabetes patient needs from more than 365 per year to just 52.
For anyone who has watched a family member manage diabetes, or lived with it personally, the daily ritual of injections is one of the most exhausting parts of the condition.
A treatment that delivers the same results with a fraction of the effort could transform compliance, reduce complications, and improve quality of life for hundreds of millions of people worldwide.
What Is Efsitora Alfa and Why Does It Matter?
Efsitora alfa is a long-acting insulin, meaning it is designed to provide a steady, background level of insulin in the body over an extended period.
Most people with type 2 diabetes who require insulin currently take what is known as basal insulin once a day.
Basal insulin does not cover meals. It simply keeps blood sugar stable between meals and overnight, acting as a baseline.
The challenge is that daily injections are easy to miss.
Research published in 2025 in the journal Patient Preference and Adherence found that nearly half of all people with diabetes report missing a dose of basal insulin within any given 30-day period.
Missed doses lead to elevated blood sugar.
Elevated blood sugar over time causes the complications that make diabetes so dangerous, including nerve damage, kidney disease, vision loss, and cardiovascular events.
Efsitora alfa is designed to make that missed-dose problem less of an issue by requiring only one injection per week.
How the Study Was Conducted
The QWINT-1 trial enrolled 795 adults with type 2 diabetes who had never used insulin therapy before.
Participants were randomly assigned to one of two groups.
Half received a once-weekly injection of efsitora alfa, starting at a fixed dose of 100 units.
The other half received the standard once-daily injection of insulin glargine, one of the most widely prescribed basal insulins in the world.
The trial ran for 52 weeks, covering a full year of treatment.
Dose adjustments for efsitora alfa were made every four weeks, with only four possible fixed dose options: 100, 150, 250, or 400 units.
By contrast, participants on glargine had their doses adjusted weekly or even more frequently, which is standard practice but considerably more demanding.
The main outcome researchers measured was the change in HbA1c levels, which is the standard long-term marker for blood sugar control.
HbA1c measures the percentage of haemoglobin in the blood that has glucose attached to it, giving a picture of average blood sugar over roughly three months.
The lower the HbA1c, the better the blood sugar control.
The trial was a large-scale global study, with participants recruited across the United States, Canada, Mexico, and several other countries.
Findings From the Study
The results were striking in their consistency.
At the start of the trial, average HbA1c levels were 8.20% in the efsitora group and 8.28% in the glargine group, both well above the recommended target of below 7%.
After 52 weeks, the efsitora group saw their average HbA1c fall to 7.05%, while the glargine group fell to 7.08%.
That is a statistically equivalent result, meaning once-weekly insulin performed just as well as once-daily insulin at controlling blood sugar over a full year.
But the blood sugar numbers are only part of the story.
Body weight also improved in both groups over the course of the trial, a welcome secondary effect.
Perhaps more importantly, the efsitora group experienced approximately 40% fewer hypoglycaemic events compared to the glargine group.
Hypoglycaemia, or dangerously low blood sugar, is one of the most feared risks of insulin therapy.
It can cause dizziness, confusion, seizures, and in severe cases, loss of consciousness.
The fact that the weekly injection produced fewer of these episodes is a meaningful safety advantage.
The results were presented to thousands of diabetes specialists and published simultaneously in some of the world’s most respected medical journals.
The Simplicity Advantage Nobody Talks About Enough
Here is what most people get wrong when they hear about a new diabetes drug.
They focus on whether it is more powerful, whether it cuts HbA1c by a larger margin, or whether it produces more dramatic weight loss.
But for the majority of people living with type 2 diabetes, the biggest barrier to good health is not the effectiveness of their medication, it is the difficulty of taking it consistently.
Daily injections require patients to remember every single day, to carry supplies, to find a private space, to manage dosing schedules alongside food and activity.
For elderly patients, patients with limited mobility, patients in low-resource settings, or patients who travel frequently, this routine creates constant friction.
That friction leads to missed doses, and missed doses lead to poor control, and poor control leads to the complications that cost lives and place enormous strain on healthcare systems.
The QWINT program enrolled more than 3,000 people with type 2 diabetes across four global registration studies, making these among the most comprehensive weekly insulin trials ever conducted.
The simplicity of the dosing schedule is not a minor convenience.
It is a potential game changer for the hundreds of millions of people worldwide who struggle not with access to treatment, but with the daily burden of sustaining it.
What Makes a Weekly Insulin Biologically Possible?
It is a reasonable question: how does an insulin last an entire week in the body when the most advanced daily insulins typically last 24 hours?
Standard basal insulins like glargine and degludec are designed to release slowly into the bloodstream after injection, providing a gradual, steady effect over roughly 24 hours.
Efsitora alfa takes a different structural approach.
It is an insulin Fc-fusion protein, meaning it is engineered by attaching an insulin molecule to the Fc region of an antibody.
This modification dramatically extends how long the molecule remains active in the body, allowing it to maintain therapeutic insulin levels across a full seven days from a single subcutaneous injection.
The body does not break it down as quickly, and its effect does not peak and trough as sharply, which may partly explain the lower rate of hypoglycaemia seen in the trials.
This technology represents a genuine leap in insulin design, not just an incremental adjustment to existing formulations.
How the Study Applies to Real Life
The numbers from a clinical trial can sometimes feel abstract.
So consider what a shift to once-weekly insulin would actually mean for a person living with type 2 diabetes today.
Under the current standard of care, a patient starting basal insulin faces a daily commitment for the rest of their life.
That means roughly 365 injections per year, alongside weekly or more frequent dose adjustments based on fasting blood glucose readings.
A once-weekly regimen with efsitora would eliminate more than 300 of those injections annually, based on figures cited by Eli Lilly.
Dose adjustments would happen every four weeks rather than every week, reducing the cognitive and logistical load on patients and their caregivers.
For healthcare systems managing millions of patients with diabetes, this simplification could also reduce the frequency of clinical check-ins required to fine-tune dosing, freeing up appointments and reducing costs.
The global scale of this matters.
A further 97.6 million American adults have prediabetes, a condition that dramatically raises the risk of progressing to type 2 diabetes.
Globally, the numbers are far larger.
Any treatment that improves long-term adherence at this scale has implications that go well beyond individual patients.
Who Is This Treatment For?
Based on the QWINT trials, efsitora alfa was tested in three distinct groups.
QWINT-1 focused on adults with type 2 diabetes who had never previously used insulin, making it particularly relevant for patients transitioning from oral medications to insulin for the first time.
QWINT-3 evaluated patients who had already been using daily basal insulin, testing whether a switch to weekly insulin could maintain the same level of control.
QWINT-4 looked at patients on multiple daily insulin injections, including both basal and mealtime insulin, representing the most complex group.
All three trials produced results that met the standard for non-inferiority, meaning efsitora performed at least as well as the daily comparators across a very broad range of patients.
This breadth is significant.
It suggests the once-weekly approach is not limited to a narrow subgroup of patients but could potentially apply to a wide portion of the type 2 diabetes population that requires insulin.
Where Things Stand Now
As of the time of writing, efsitora alfa has not yet received regulatory approval.
Lead investigator Dr. Julio Rosenstock, senior scientific advisor at Velocity Clinical Research in Dallas and a clinical professor at the University of Texas Southwestern Medical Center, described the results in clear terms.
“The results confirm once-weekly insulin efsitora can deliver similar level of blood sugar control as daily basal insulin, with the added benefit of a simpler dosing schedule.”
If regulators approve efsitora, it will not replace all forms of insulin therapy.
Patients who also need mealtime insulin, or those managing type 1 diabetes, will still require additional treatment.
Eli Lilly has confirmed it does not currently plan to pursue efsitora as a treatment for type 1 diabetes, citing a different benefit-risk profile for that population.
But for the large and growing number of people with type 2 diabetes who need basal insulin and struggle with the daily demands of current therapy, this could represent one of the most practical advances in diabetes care in years.
The Bigger Picture for Diabetes Treatment
It is worth stepping back and acknowledging how much the landscape of diabetes treatment has shifted in a short period.
Drugs like tirzepatide, approved by the FDA in 2022, already showed that once-weekly injections could deliver powerful effects on both blood sugar and body weight, reducing the risk of progressing from prediabetes to type 2 diabetes by up to 94% in one major trial.
Now, weekly basal insulin is entering the picture for those who are already well into the disease.
The common thread running through all of these advances is the same: less frequent, less burdensome treatment that patients are more likely to actually stick to.
That insight, arguably as much as any chemical innovation, may be what moves the needle on diabetes outcomes over the next decade.
Because a perfect drug taken inconsistently will never outperform a good drug taken reliably.
The science is promising, the trial results are robust, and the need is clear.
Whether efsitora alfa ultimately reaches patients at scale depends on regulatory decisions, pricing, and healthcare access, all of which matter enormously and are still unresolved.
But the question it poses is one worth sitting with: if the biggest obstacle to controlling a chronic disease is simply the daily friction of treatment, what does it mean for medicine to finally start addressing that directly?
References and Further Reading
